Dye-stabilized nanoparticles and methods of their manufacture and therapeutic use

Abstract

Described herein are nanoparticles which are largely made of (e.g., 90 wt. %) hydrophobic drugs and are stabilized by water soluble dyes. The nanoparticles can range in size from 30 nm to 150 nm and have highly negative surface charge (e.g., −55 mV). These nanoparticles are highly soluble in water, stable for days in PBS buffer and can be easily lyophilzed and reconstituted in water. Using quantitative self-assembly prediction calculations, topochemical molecular descriptors were identified and validated as highly predictive indicators of nano-assembly, nanoparticle size, and drug loading. The resulting nanoparticles selectively targeted kinase inhibitors to caveolin-1expressing human colon cancer and autochthonous liver cancer models to yield striking therapeutic effects while avoiding pERK inhibition in healthy skin. The nanoparticles exhibited remarkable anti-tumor efficacy in vitro and in vivo in models of hepatocellular carcinoma.

Description

CROSS REFERENCE TO RELATED APPLICATION[0001]This application is a continuation of U.S. patent application Ser. No. 15 / 549,985, filed Aug. 9, 2017, which is a National Stage Application of PCT / US2016 / 017153, filed Feb. 9, 2016, which claims the benefit of U.S. patent application Ser. No. 62 / 114,507, filed Feb. 10, 2015, the entire disclosures of each of which are hereby incorporated by reference in their entireties.GOVERNMENT SUPPORT[0002]This invention was made with government support under HD075698 and CA008748 awarded by the National Institutes of Health and MCB0130013 awarded by the National Science Foundation. The government has certain rights in this invention.FIELD OF THE INVENTION[0003]This invention relates generally to nanoparticles and methods of their manufacture and therapeutic use. In particular embodiments, the invention relates to dye-stabilized nanoparticles for the treatment of cancer and other diseases.BACKGROUND[0004]Many FDA approved and non-approved small molecu...

AI Technical Summary

Benefits of technology

The patent text describes a new way to create nanoparticles that can carry drugs specifically to tumor cells. These nanoparticles are made by using molecules that are already used as drugs. The nanoparticles are predicted to have high negative charges and are soluble in water. They can also be stored for days and easily dissolved in water. The nanoparticles have been tested in animal models and have shown promising results in treating tumors while avoiding harmful side effects on healthy cells. This new technology makes it possible to create targeted drug delivery systems with high drug loadings and specific targeting capabilities.

Problems solved by technology

Many FDA approved and non-approved small molecule drugs suffer from poor water solubility, rapid clearance and relatively low concentration at site of disease.

In cancer patients, systemically-delivered chemotherapy is often highly toxic, limiting the dose.

In addition, potentially therapeutic new molecules are often too toxic to deliver using conventional routes, preventing their further development.

Even as new molecularly targeted therapies are increasingly reaching the clinic, it is apparent that even such drugs often exhibit serious side-effects due to off-target responses.

However, cyanine dyes at concentrations above 0.5% in water are known to self-assemble into aggregates and form chromatic liquid crystals, thereby limiting the efficacy of the therapeutic (Harrison et al., Journal of physical chemistry, 100.6 (1996): 2310-2321; Wu finer et al., Angewandte Chemie International Edition, 50.15 (2011): 3376-3410).

However, the aggregates formed at low concentrations are not large enough to align, and, at larger concentrations, aggregate size increases into supra-molecular assemblies.

A limitation of targeted nanoparticle drug carrier design is that complex synthetic schemes are often required, resulting in low loadings and higher barriers to clinical translation.

The synthesis of nanoscale drug delivery vehicles is highly dependent on drug chemistry, and synthetic strategies seldom benefit from a priori information.

This can also result in processes that are often unpredictable and based on trial-and-error methods.

Crossing the vascular endothelial barriers remains a major challenge for developing efficient, targeted nanoparticle drug delivery systems for cancer therapy.

These processes are generally difficult to predict, execute, and control.

However, these quantitative approaches have not yet enabled appreciable predictive power to facilitate the synthesis of drug carrier nanomaterials.

Images